NCT03511898View on ClinicalTrials.gov

A Study to Evaluate the Safety of THR-149 in Subjects With Diabetic Macular Edema (DME)

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 18, 2018

Primary Completion Date

May 22, 2019

Study Completion Date

May 22, 2019

Conditions
Diabetes MellitusDiabetic RetinopathyDiabetic Macular Edema
Interventions
DRUG

THR-149 dose level 1

single intravitreal injection of THR-149 dose level 1

DRUG

THR-149 dose level 2

single intravitreal injection of THR-149 dose level 2

DRUG

THR-149 dose level 3

single intravitreal injection of THR-149 dose level 3

Trial Locations (7)

19006

Mid Atlantic Retina, Huntingdon Valley

77030

Retina Consultants of Houston, Houston

78705

Retinal Research Center, PLLC, Austin

79606

Retina Research Institute of Texas, Abilene

85053

Retina Consultants of Arizona, Phoenix

89502

Sierra Eye Associates, Reno

02114

Ophthalmic Consultants of Boston, Boston

Sponsors

Lead Sponsor

ThromboGenics
All Listed Sponsors
lead

ThromboGenics

INDUSTRY

NCT03511898 - A Study to Evaluate the Safety of THR-149 in Subjects With Diabetic Macular Edema (DME) | Biotech Hunter | Biotech Hunter